BioStock: First patient dosed in Spago’s phase I/IIa trial

Spago Nanomedical recently received approval to start the phase I/IIa study with Tumorad in Australia. The study is now well on its way as the company announced last week that the first patient has been successfully dosed. BioStock reached out to Spago's Chief Development Officer Paul Hargreaves to learn more.

Read the interview with Paul Hargreaves at biostock.se:

First patient dosed in Spago’s phase I/IIa trial - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/